Highly efficient and eco-innovative probiotic food supplement for antibiotic-associated disorders prevention

Project Information

AB-Prevention

Grant agreement ID: 717273

DOI 10.3030/717273

Closed project

EC signature date 26 February 2016

Start date 1 March 2016

End date 31 May 2016

Funded under

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

MYBIOTICS PHARMA LTD
Israel

Objective

Development of novel probiotic solutions for specific illnesses and health problems, ex: Obesity, Depression, Crohn or Colitis diseases.

The solutions proposed by MyBiotics will use Mycrobe TM a delivery technology to overpass the biologic barriers :gastric acid, pancreatic juice and bile salts, and deliver sufficient quantity of living probiotic directly to colonize the gastro intestinal tract were they are therapeutically efficient.

MyBiotics will design for each targeted disease a set of specific bacteria and validate their selection by using MycrobeTM as leverage to provide unreached comfort and easy variation during the selection and test of the probiotics.

The ambition is to provide pharmabiotic solutions for specific diseases and provide robust clinical results for lobbying activities with the EMA, EFSA and FDA for the regulation

Fields of science

• natural sciences › biological sciences › microbiology › bacteriology
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › antibiotics
• medical and health sciences › health sciences › nutrition › obesity

Programme(s)

• H2020-EU.3.2. - SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Topic(s)

• SFS-08-2015-1 - Resource-efficient eco-innovative food production and processing

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2015

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

MYBIOTICS PHARMA LTD

• Net EU contribution: € 50 000,00
• Address: 5 GOLDA MEIR BLVD, RTH FLOOR ; 7414001 Ness Ziona ; Israel
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Activity type
  Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00